Comparison of the clinical effect of different doses of rosuvastatin in the treatment of hyperlipidemia and carotid atherosclerotic plaque in young ischemic stroke patients
10.3760/cma.j.issn.1008-6706.2016.22.006
- VernacularTitle:不同剂量瑞舒伐他汀治疗青年缺血性卒中患者高脂血症和颈动脉粥样硬化斑块的临床效果比较
- Author:
Kai WANG
;
Liangqun RONG
;
Xiue WEI
- Publication Type:Journal Article
- Keywords:
Brain ischemic;
Hyperlipidemia;
Rosuvastatin;
Carotid atherosclerosis plaque
- From:
Chinese Journal of Primary Medicine and Pharmacy
2016;23(22):3383-3388
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy and safety of rosuvastatin in the treatment of hyperlipidemia and carotid atherosclerotic plaque in young ischemic stroke patients.Methods In prospective study,264 young ischemic stroke patients with hyperlipidemia and carotid atherosclerotic plaque were randomly divided into low dose group,middle dose group,high dose group,88 cases in each group.All patients were given rosuvastatin immediately after dinner,in doses of 5mg,10mg,20mg,respectively,for eight months.Then,the changes of hyperlipidemia and carotid atherosclerotic plaque in the three groups were surveyed,and its safety by the observation of clinical symptoms and monitoring of adverse reactions after eight months were assessed.Results Before treatment,the blood fat and carotid atherosclerosis plaque index in the three groups had no statistically significant differences (all P >0.05). After treatment,the total cholesterol,triglycerides,low -density lipoprotein cholesterol of the high dose group were (1.67 ±0.68)mmol/L,(3.23 ±0.53)mmol/L,(1.83 ±0.62)mmol/L,which of the middle dose group were (1.93 ±0.74)mmol/L,(3.73 ±0.23)mmol/L,(2.24 ±0.73)mmol/L,which of the low dose group were (2.16 ± 0.77)mmol/L,(4.06 ±0.93)mmol/L,(2.93 ±0.35)mmol/L.These indicators were decreased than before treat-ment [(2.79 ±0.72)mmol/L,(5.40 ±0.67)mmol/L,(3.64 ±1.03)mmol/L,(2.75 ±0.81)mmol/L,(5.59 ± 0.95)mmol/L,(3.43 ±0.92)mmol/L and (2.83 ±0.53)mmol/L,(5.84 ±0.79)mmol/L,(3.83 ±0.88)mmol/L].The decrease of the high dose group was higher than the middle and low dose group,the difference was statistically significant(F =6.61,P <0.05).The effective rate of the high dose group was 85.23%.which of the middle dose group was 76.14%.The effective rate of the low dose group was 62.50%.The efficacy of the high dose group was better than the middle dose group and low dose group,the difference was statistically significant(χ2 =5.79,P <0.05).After treatment,the intima -media thickness,plaque area and Crouse score of the high dose group were (0.92 ±0.41)mm,(0.52 ±0.56 )mm,(3.07 ±0.58 )mm,which of the middle dose group were (1.11 ± 0.52)mm,(0.60 ±0.36)mm,(3.39 ±0.83)mm,which of the low dose group were (1.42 ±0.87)mm,(0.81 ± 0.91)mm,(4.09 ±0.77)mm,which were decreased than before treatment[(1.71 ±0.89)mm,(0.86 ±0.55)mm, (4.39 ±0.19)mm,(1.74 ±1.03)mm,(0.89 ±0.48)mm,(4.42 ±0.53)mm and (1.68 ±0.96)mm,(0.87 ± 0.61)mm,(4.38 ±0.22)mm].The decrease of the high dose group was higher than the middle and low dose group, the difference was statistically significant (F =5.83,P <0.05 ).The effective rate of the high dose group was 78.41%.The effective rate of the middle dose group was 52.27%.The effective rate of the low dose group was 30.68%.The efficacy of the high dose group was better than the middle dose group and low dose group,the difference was statistically significant(χ2 =5.37,P <0.05).There were 10 cases (11.36%)had adverse reaction in the low dose group,12 cases (13.64%)in the middle dose group,14 cases (15.91%)in the high dose group.There was no statistically significant difference in incidence of adverse reactions among the three groups (P >0.05),and no serious adverse reaction was found.Conclusion The high dose rosuvastatin treatment can reverse the nature of plaque, decrease the thickness of the plaques and lower blood lipid of young ischemic stroke with hyperlipidemia and carotid atherosclerotic plaque,which is better than middle and low dose,and has better security.There is no serious adverse reaction.It is worth for clinical promotion.
